CompletedPHASE1, PHASE2NCT00867321
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Steven R. Alberts, MD, M.D., Ph.DMayo Clinic
- Intervention
- bevacizumab(biological)
- Enrollment
- 24 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2009 – 2013
Study locations (30)
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- Aurora Presbyterian Hospital, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
- St. Anthony Central Hospital, Denver, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States
- St. Joseph Hospital, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- CCOP - Colorado Cancer Research Program, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center, Grand Junction, Colorado, United States
- North Colorado Medical Center, Greeley, Colorado, United States
- Sky Ridge Medical Center, Lone Tree, Colorado, United States
- Hope Cancer Care Center at Longmont United Hospital, Longmont, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00867321 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital